-- Jefferies on Monday reduced its price target for Saudi Awwal Bank (SASE:1060) to 44 Saudi riyals from 49 riyals, while maintaining its buy rating.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:FY 26 (Mar.) EPADS rose 5.1% to INR149.54, beating our flattish estimate due to better-than-projected loan growth (+15.8%; of which, business banking: +24.4%; retail and corporate loans: +9% to +10%), NIM (stable at 4.32%), and non-banking income. We think robust demand from SMEs, the positive impact of the 0%-GST reform in September 2025 on consumer spending, and the strong housing market will sustain loan momentum into FY 27. We see some pressure on NIM from the 25-bp cut in the benchmark repo rate in December 2025, but expect ICICI's NIM to stay range-bound and industry leading, aided by faster growth in higher-yielding business loans and ICICI's relatively high mix of CASA deposits (at about 41.4% of total deposits at end-FY 26). Asset quality was solid. Provision charges rose 14.9% in FY 26 due to an additional standard asset provision set aside for agricultural priority sector credit facilities, but there is no change in the portfolio's asset quality. We expect provision charges to ease in FY 27.
Orient Securities (HKG:3958, SHA:600958) plans to fully acquire Shanghai Securities through share placement and cash, according to a Hong Kong filing on Sunday.The securities broker entered into an agreement of intent with Shanghai Securities' five shareholders, including Shanghai International Group and Guotai Haitong Securities (SHA:601211, HKG:2611).The merger is expected to create a firm with combined assets worth about $86 billion, according to their latest financial statements, Bloomberg News reported Sunday.The trading of Orient Securities' shares was suspended starting Monday and is expected to last for up to 10 trading days.
Emyria (ASX:EMD) launched its Empax Global Partnership Program, a services platform allowing international drug sponsors to access the company's clinical delivery infrastructure, according to a Monday filing with the Australian bourse.The launch establishes a dual-revenue model combining existing reimbursed treatment programs with sponsor-funded services, the filing said.The company's shares jumped almost 19% in recent Monday trade.